Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series

Abstract excerpt

Poly (ADP-ribose) polymerase (PARP) inhibitors interact with DNA at single-strand breaks, prevent repair, and generate irreparable double-strand breaks that lead to tumor cell death [ 1 ]. Patients who harbor defects in homologous recombination repair, such as those with BRCA mutations, have tumors that are especially sensitive to PARP inhibitors.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Chronic Lymphocytic Leukemia Research
• Share to PARP inhibition in cancer therapy